Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Verifiedinfo

Universitaet Rostock

Germany Schillingallee 35, Hansaviertel, 18057 Rostock, Germany

  • 3 trials recruiting
  • Transitional cell carcinoma · Acute myeloid leukaemia
  • Adults and children

About Specializations

Universitaet Rostock in Rostock, Germany specialises in clinical trials of conditions such as Transitional cell carcinoma, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms Research at Universitaet Rostock

The department of Medizinische Klinik III für Hämatologie, Onkologie und Palliativmedizin concentrates on blood‑related cancers, seeking better therapies for both adult and pediatric patients.

  • Acute Myeloid Leukemia (AML)
  • Relapsed Acute Lymphoblastic Leukemia (ALL)
  • Optimization of chemotherapy dosing
  • Evaluation of novel agents such as L‑Annamycin
  • Assessment of bortezomib‑based induction regimens

Current studies aim to raise complete remission rates and define the most effective dosage schedules, offering new hope for patients with high‑risk or refractory disease at this European research site.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Schillingallee 35, Hansaviertel18057 RostockGermany
Open in maps ↗
Recruiting now
3 trials
Conditions studied
2
Partner status
Verified

More sites in RostockGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

3 clinical trials

Transitional cell carcinoma

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Acute myeloid leukaemia

Recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Annamycin
  • Sponsor:Moleculin Biotech Inc.

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.